Polycythemia Vera Market: Is 2026 the Year the "Phlebotomy-Free" Dream Becomes Reality?
As of January 2026, the global polycythemia vera (PV) market is identifying as a rapidly expanding sector within hematology, with its 2026 valuation estimated at approximately $1.53 billion. The 2026 landscape is defined by the high-stakes U.S. FDA submission of Rusfertide, a first-in-class hepcidin mimetic that could virtually eliminate the need for therapeutic phlebotomy. This 2026 milestone...
0 Commenti 0 condivisioni 26 Views 0 Anteprima
Realfrd – Build Friendships That Last https://realfrd.com